Supplementary Figure 6 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer

Izuchukwu F. Okpalanwaka; Elizabeth A. Daugherity; Amanda L. McCormick; Trevor S. Anderson; Savanna L. Smith; Caryn Lawrence; Duke Appiah; Devin B. Lowe

doi:10.1158/1535-7163.29760632

August 1, 2025

Supplementary Figure 6 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer

View at Publisher

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: Treatment with a PD-L1/CD3 bispecific antibody and regorafenib enhances anti-tumor immunity.
KEY EVIDENCE: Observations show improved type-1 immunity in the CT26 tumor microenvironment after treatment.
APPROACH: The study utilizes supplementary figure analysis to visualize immune changes post-therapy in colon cancer models.
SIGNIFICANCE: This research suggests new strategies that leverage immune responses to fight colon cancer more effectively.

Implication

Supplementary figure reveals enhanced type-1 immunity in CT26 tumor microenvironment after regorafenib and bispecific antibody therapy, suggesting a novel treatment pathway for colon cancer.

Abstract

Supplementary Figure 6 indicates improved Type-1-mediated immunity in the CT26 TME post REG/bsAb treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Okpalanwaka et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d01c9 https://doi.org/10.1158/1535-7163.29760632

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure 6 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure 6 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading